We Offer Worldwide Shipping
Login Wishlist

8α-Hydroxyhirsutinolide

$1,400

  • Brand : BIOFRON

  • Catalogue Number : BN-B0768

  • Specification : 98%(HPLC)

  • CAS number : 1394156-45-6

  • Formula : C15H20O6

  • Molecular Weight : 296.32

  • PUBCHEM ID : 70690654

  • Volume : 5mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BN-B0768

Analysis Method

HPLC,NMR,MS

Specification

98%(HPLC)

Storage

2-8°C

Molecular Weight

296.32

Appearance

Powder

Botanical Source

Structure Type

Sesquiterpenoids

Category

Standards;Natural Pytochemical;API

SMILES

CC1CC(C2=C(C(=O)OC2=CC3(CCC1(O3)O)C)CO)O

Synonyms

(1R,2E,8S,10R,11S)-8,11-Dihydroxy-6-(hydroxymethyl)-1,10-dimethyl-4,14-dioxatricyclo[9.2.1.03,7]tetradeca-2,6-dien-5-one/7,10-Epoxycyclodeca[b]furan-2(4H)-one, 5,6,7,8,9,10-hexahydro-4,7-dihydroxy-3-(hydroxymethyl)-6,10-dimethyl-, (4S,6R,7S,10R,11E)-

IUPAC Name

(1R,2E,8S,10R,11S)-8,11-dihydroxy-6-(hydroxymethyl)-1,10-dimethyl-4,14-dioxatricyclo[9.2.1.03,7]tetradeca-2,6-dien-5-one

Density

1.4±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

222.7±23.6 °C

Boiling Point

587.4±50.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C15H20O6/c1-8-5-10(17)12-9(7-16)13(18)20-11(12)6-14(2)3-4-15(8,19)21-14/h6,8,10,16-17,19H,3-5,7H2,1-2H3/b11-6+/t8-,10+,14-,15+/m1/s1

InChl Key

HGVUPZFNJFDVQM-HEQUYQGPSA-N

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:1394156-45-6) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

18687133

Abstract

Background
The objective was to study the association between Non-Hodgkin’s Lymphoma (NHL) and occupational exposures related to long held occupations among males in six provinces of Canada.

Methods
A population based case-control study was conducted from 1991 to 1994. Males with newly diagnosed NHL (ICD-10) were stratified by province of residence and age group. A total of 513 incident cases and 1506 population based controls were included in the analysis. Conditional logistic regression was conducted to fit statistical models.

Results
Based on conditional logistic regression modeling, the following factors independently increased the risk of NHL: farmer and machinist as long held occupations; constant exposure to diesel exhaust fumes; constant exposure to ionizing radiation (radium); and personal history of another cancer. Men who had worked for 20 years or more as farmer and machinist were the most likely to develop NHL.

Conclusion
An increased risk of developing NHL is associated with the following: long held occupations of faer and machinist; exposure to diesel fumes; and exposure to ionizing radiation (radium). The risk of NHL increased with the duration of employment as a farmer or machinist.

Title

Occupational exposures and non-Hodgkin's lymphoma: Canadian case-control study

Author

Chandima P Karunanayake,1 Helen H McDuffie,1 James A Dosman,1 John J Spinelli,2 and Punam Pahwacorresponding author1,3

Publish date

2008

PMID

24823806

Abstract

Animals are frequently used as model systems for determination of safety and efficacy in pharmaceutical research and development. However, significant quantitative and qualitative differences exist between humans and the animal models used in research. This is as a result of genetic variation between human and the laboratory animal. Therefore the development of a system that would allow the assessment of all molecular differences between species after drug exposure would have a significant impact on drug evaluation for toxicity and efficacy. Here we describe a cross-species microarray methodology that identifies and selects orthologous probes after cross-species sequence comparison to develop an orthologous cross-species gene expression analysis tool. The assumptions made by the use of this orthologous gene expression strategy for cross-species extrapolation is that; conserved changes in gene expression equate to conserved pharmacodynamic endpoints. This assumption is supported by the fact that evolution and selection have maintained the structure and function of many biochemical pathways over time, resulting in the conservation of many important processes. We demonstrate this cross-species methodology by investigating species specific differences of the peroxisome proliferator-activator receptor (PPAR) α response in rat and human.

Title

Cross-Species Gene Expression Analysis of Species Specific Differences in the Preclinical Assessment of Pharmaceutical Compounds

Author

John Okyere, 1 , * Ekow Oppon, 1 Daniel Dzidzienyo, 1 Lav Sharma, 1 and Graham Ball 2

Publish date

2014;


Description :

Empty ...